These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10465932)

  • 1. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.
    Ding AA; Wu H
    Math Biosci; 1999 Aug; 160(1):63-82. PubMed ID: 10465932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher antiviral activity of antiretroviral regimens including protease inhibitors.
    de Mendoza C; Soriano V; Rodríguez-Rosado R; González-Lahoz J
    AIDS; 1999 May; 13(8):998-9. PubMed ID: 10371186
    [No Abstract]   [Full Text] [Related]  

  • 3. [HIV viral dynamic after antiretroviral treatment initiation: is a rapid decay a good pronostic?].
    Delaugerre C
    Pathol Biol (Paris); 2010 Dec; 58(6):403-5. PubMed ID: 19481371
    [No Abstract]   [Full Text] [Related]  

  • 4. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.
    Sedaghat AR; Dinoso JB; Shen L; Wilke CO; Siliciano RF
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4832-7. PubMed ID: 18362342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity.
    Huang Y; Rosenkranz SL; Wu H
    Math Biosci; 2003 Aug; 184(2):165-86. PubMed ID: 12832146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New wave antiretrovirals.
    Smart T
    GMHC Treat Issues; 1996 Sep; 10(9):1-3. PubMed ID: 11363838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 9. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New information on HIV rapid turnover--what does it mean?
    James JS
    AIDS Treat News; 1995 Jan; (No 215):1-4. PubMed ID: 11362214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral dynamics in human immunodeficiency virus type 1 infection.
    Wei X; Ghosh SK; Taylor ME; Johnson VA; Emini EA; Deutsch P; Lifson JD; Bonhoeffer S; Nowak MA; Hahn BH
    Nature; 1995 Jan; 373(6510):117-22. PubMed ID: 7529365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group.
    Lindbäck S; Karlsson AC; Mittler J; Blaxhult A; Carlsson M; Briheim G; Sönnerborg A; Gaines H
    AIDS; 2000 Oct; 14(15):2283-91. PubMed ID: 11089616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV therapeutics.
    Richman DD
    Science; 1996 Jun; 272(5270):1886-8. PubMed ID: 8658159
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
    Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
    Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
    [No Abstract]   [Full Text] [Related]  

  • 15. What's new in HIV.
    Morris-Jones S; Nelson MR
    J Infect; 1999 Mar; 38(2):i-ii. PubMed ID: 10342641
    [No Abstract]   [Full Text] [Related]  

  • 16. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The daunting challenge of keeping HIV suppressed.
    Cohen J
    Science; 1997 Jul; 277(5322):32-3. PubMed ID: 9229768
    [No Abstract]   [Full Text] [Related]  

  • 18. The brightening future of HIV therapeutics.
    Greene WC
    Nat Immunol; 2004 Sep; 5(9):867-71. PubMed ID: 15334078
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
    J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High turnover of HIV in blood revealed by new studies.
    Cohen J
    Science; 1995 Jan; 267(5195):179. PubMed ID: 7809623
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.